Valerio Therapeutics Société anonyme (0NWK.L)

0,1229 -0,1496 (-54,90%) Alla chiusura: 06:55PM BST

Valerio Therapeutics Société anonyme

49, boulevard du Général Martial Valin
Paris 75015
France
33 1 70 38 33 99
https://valeriotx.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 19

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Shefali Agarwal M.D., MPH	President, CEO & Chairwoman	N/D	N/D	1973
Ms. Joyce Carey	Executive Director of Finance and Head of FP&A	N/D	N/D	N/D
Ms. Robin Sutherland	VP & Global Head of Human Resources	N/D	N/D	N/D
Mr. Michel Forest	Chief Pharmacist & Quality Assurance Director	N/D	N/D	N/D
Ms. Huiping Jiang	Senior Vice President of Regulatory Affairs & Quality Assurance	N/D	N/D	N/D
Mr. Wael Jdey Ph.D.	Head of Preclinical	N/D	N/D	N/D
Dr. Donna Cabral-Lilly Ph.D.	VP & Head of CMC	N/D	N/D	N/D
Ms. Pam Slatcher	Head of Global PV	N/D	N/D	N/D

Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops AsiDNA, which is in Phase 1b/2 trial in combination with the PARP inhibitor Olaparib to evaluate safety in patients with epithelial ovarian cancer, breast cancer, and metastatic castration-resistant prostate cancer. It also develops Revocan that is in Phase 1b/2 trial to evaluate the addition of AsiDNA to combat PARP inhibitor resistance in second-line maintenance treatment of recurrent ovarian cancer, as well as in phase 1b/2 trial evaluating AsiDNA in combination with radiotherapy in recurrent highgrade glioma in children. In addition, it is developing VIO-01, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, a chemistry platform for building new molecules, which include OX400, a decoy DNA platform. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. The company was founded in 1997 and is headquartered in Paris, France.

Governance aziendale

L'ISS Governance QualityScore di Valerio Therapeutics Société anonyme al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.